alphafold

10+ articles

AI AI Innovation AI Regulation AI Startups AI Weaponization

One Man, His Dog, and ChatGPT: Australia's AI-Powered Vaccine Revolution

Australian tech entrepreneur Paul Cunningham turned to AI, leveraging ChatGPT and AlphaFold, to create a personalized mRNA cancer vaccine for his dog, Rose. Partnering with UNSW, the vaccine was developed in record time, shrinking Rose's tumor significantly. This breakthrough underscores AI's potential in personalized medicine and paves the way for innovations in both veterinary and human healthcare.

Mar 30

One Man, His Dog, and ChatGPT: Australia's AI-Powered Vaccine Revolution

A New Challenger Appears: IntelliGen AI Takes Aim at Google DeepMind in Drug Discovery

IntelliGen AI, a fresh face in the Hong Kong tech scene, is setting its sights on the big leagues, taking on Google DeepMind in the high-stakes arena of AI-driven drug discovery. With their cutting-edge IntFold model, IntelliGen is betting on generative science to make waves in the biotech world, promising faster drug development and innovative solutions. Founder Ronald Sun is optimistic about their chances to revolutionize the industry within the next 18 months.

Jul 11

A New Challenger Appears: IntelliGen AI Takes Aim at Google DeepMind in Drug Discovery

DeepMind's Bold Prediction: Could AI Eradicate All Diseases in a Decade?

Google DeepMind CEO Demis Hassabis claims that AI could potentially cure all diseases within the next decade. Hassabis highlights the transformative power of AI in drug discovery, with DeepMind's AI identifying over 200 million protein structures to accelerate drug development. While this prediction excites many, it also raises questions about the feasibility, ethical considerations, and challenges of aligning AI with human values.

Apr 22

DeepMind's Bold Prediction: Could AI Eradicate All Diseases in a Decade?

AI's Grand Ambition: Google DeepMind CEO Predicts a Disease-Free Decade

Demis Hassabis, CEO of Google DeepMind, envisions a future where AI could potentially cure all diseases within ten years. This ambitious claim is backed by Aravind Srinivas, CEO of Perplexity AI, highlighting AI's transformative potential in drug discovery and personalized medicine. Learn how AI like AlphaFold is revolutionizing health research and the potential challenges ahead.

Apr 22

AI's Grand Ambition: Google DeepMind CEO Predicts a Disease-Free Decade

VantAI Unveils Neo-1: The AI Marvel Designing Molecular Glues for Drug Discovery

VantAI, a spinout of Roivant Sciences, has introduced Neo-1, a trailblazing AI model in the realm of drug discovery. Neo-1 not only predicts biomolecular structures but also generates new molecules, potentially crafting molecular glues that could transform the pharmaceutical landscape by targeting previously undruggable proteins.

Mar 22

VantAI Unveils Neo-1: The AI Marvel Designing Molecular Glues for Drug Discovery

MIT Unveils ProtGPS: Pioneering AI Uncovers Protein Travel Plans

MIT's revolutionary ProtGPS AI model is turning heads by predicting the destinations of proteins within cells, based on amino acid sequences. Not only can it predict the travel plans of proteins across 12 cell compartments, but it's also making waves in understanding how mutations can disrupt these routes, potentially transforming disease treatment. ProtGPS's accuracy and innovative approach are comparable to AlphaFold, but with a unique focus on cellular GPS for proteins.

Feb 14

MIT Unveils ProtGPS: Pioneering AI Uncovers Protein Travel Plans

Ex-DeepMind Scientist Embarks on AI-Driven Drug Discovery Adventure!

A former DeepMind scientist has launched a pioneering venture focused on leveraging AI to innovate the drug discovery process. Building on successes like AlphaFold, the project aims to revolutionize pharmaceutical development by expediting timelines and cutting costs. As the AI drug discovery market expands, this initiative highlights the growing intersection of technology and healthcare.

Feb 13

Ex-DeepMind Scientist Embarks on AI-Driven Drug Discovery Adventure!

AI: Driving Transformation in the UK and Internationally

Explore how AI is shaping economies and regulations across the globe, and why the UK is emphasizing balanced growth over mere compliance with international norms.

Jan 26

AI: Driving Transformation in the UK and Internationally

DeepMind CEO Announces AI-Developed Drug to Hit Clinical Trials by Year's End

DeepMind's CEO Demis Hassabis has declared that an AI-designed drug is poised to enter clinical trials by the end of the year, marking a significant milestone in pharmaceutical development. While details about the specific drug remain scarce due to paywall restrictions, this announcement signals a potential paradigm shift, leveraging DeepMind's expertise in AI, particularly with the renowned AlphaFold system. The inclusion of AI in drug creation is anticipated to cut down traditional timelines significantly, fostering innovation in medicine.

Jan 22

DeepMind CEO Announces AI-Developed Drug to Hit Clinical Trials by Year's End

UK's AI Market: Rising to the Top with DeepMind's AlphaFold

The UK emerges as the world's third-largest AI market, showcasing immense potential for growth. With innovative companies like DeepMind leading the charge, the nation's AI capabilities are highlighted by breakthroughs such as AlphaFold. This analysis delves into the UK's competitive edge, its strategic differentiation from European policies, and proposed governmental initiatives to capitalize on AI advancements and economic potentials.

Jan 17

UK's AI Market: Rising to the Top with DeepMind's AlphaFold